Observational studyPloS one2026
Integrated multi-omics reveals dysbiosis in hemodialysis patients: A multi-center study.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe gut microbiome-metabolome interplay in hemodialysis (HD) patients remains poorly characterized. Using multi-omics approaches, we compared HD patients with healthy controls (HC) to identify microbial signatures, metabolic perturbations, and their integrated correlations.
methodsThis case-control study included 192 participants (96 HD-HC pairs under identical dietary and living conditions). The gut microbiota composition was analyzed using 16S ribosomal RNA gene sequencing, and fecal metabolomes were analyzed using ultra-high-performance liquid chromatography and high-resolution mass spectrometry (UPLC-HRMS). A multi-omics analysis was conducted utilizing Spearman correlation analysis, Mantel test analysis, and differential functional pathway analysis.
resultsWe observed significant differences in gut microbiota composition between the HD and HC groups, such as Ruminococcus and Bifidobacterium. Comparative analysis revealed 497 significantly altered metabolites in the HD group versus HC, primarily associated with amino acid, vitamin, lipid, purine, and pyrimidine metabolisms. ROC analysis identified 4-pyridoxic acid, nudifloramide, imidazoleacetic acid, ascorbic acid, and tocopheronic acid as potential diagnostic biomarkers (AUC > 0.8, p < 0.01). Integrated multi-omics analysis revealed correlations between Ruminococcus and metabolites such as Docosapentoic acid (DPA), 13 - EPAHAAB (EPA), and tryptamine, with shared differential pathways in bile secretion, caffeine metabolism, gastric acid secretion, and vitamin B6 metabolism.
conclusionHemodialysis patients exhibited significant alterations in gut microbiota composition and metabolic profiles (amino acid, vitamin, and lipid metabolism) compared with healthy controls, with demonstrated microbiome-metabolome interactions and shared functional pathways. The potential diagnostic and therapeutic value of these differential features warrants further exploration and external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.